Reactogenicity, Patient Reported Outcomes and Vaccine Preference in Adults Immunized With Recombinant Protein or mRNA COVID-19 Vaccines

Publication date: Jul 01, 2025

The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mRNA Pfizer vaccine. Specifically, the study aims to determine the rate of participant-reported symptoms associated with each type of vaccine.

Concepts Keywords
Adults COVID-19
Allergic COVID-19 immunization study
Oregon COVID-19 Patient-reported outcomes
Vaccine COVID-19 Post-vaccination symptoms
Week COVID-19 Reactogenicity
COVID-Vaccine tolerability study
Novavax
Novavax booster trial
Protein-based COVID vaccine

Semantics

Type Source Name
disease IDO protein
disease MESH infection
drug DRUGBANK Tropicamide
disease MESH substance use
disease MESH allergic reaction
disease MESH inflammation
disease MESH COVID-19

Original Article

(Visited 9 times, 1 visits today)